How to use this page
Dating raises two questions at once. When do you say something, and how much do you say? Neither has a fixed answer.
I wrote this one for someone new. The relationships guide covers a partnership already built, including one under strain.
Telling someone and treating your skin are separate decisions. You can do one without the other, in either order.
Community ideas are labeled because they vary by person. They are options, not promises about how another person will respond.
The part worth saying first
The most common wrong belief about psoriasis is that someone can catch it. Saying otherwise early takes that worry off the table.
I read the National Psoriasis Foundation page, which records psoriasis as an immune-mediated disease. An overactive immune system speeds up skin-cell growth. Cells that usually take about a month to grow and shed do it in three or four days.
Raised plaques and scale are what that looks like on the surface. So a plaque is your own immune system at work, not an infection that moves between people.
That is one sentence, not a lecture. Most people relax as soon as they hear it.
Sources for the facts above: Evidence
Lived experience - varies by person
Early, late, or by showing rather than telling
No rule sets the moment, and no version of this counts as the honest one.
Some people say it early, before it can land as a surprise. Some wait until they know the person is worth the conversation. Some never plan it, and answer a question when it finally comes.
Showing is also a way of telling. A photo, a short sleeve, or a swim can do it without a speech. Pick the route that costs you the least dread.
Timing that worked once may not fit the next person. You are allowed to change how you do this.
When a flare lands on a date week
Flares do not check your calendar. A bad week can arrive right before plans you were looking forward to.
I read the American Academy of Dermatology list of flare triggers: stress, skin injury, infection, starting some medicines, and cold, dry weather. It also says triggers differ from person to person.
So a flare on a date week is not proof that you handled something badly. Your own pattern is the part you can work on.
I looked at the National Psoriasis Foundation tracker page, which suggests tracking symptoms and triggers over time, then sharing that record with a clinician. A plan you already trust makes a surprise week less loud.
Intimacy, and skin a date has not seen
Psoriasis in the genital area or a skin fold raises a different question than a plaque on an elbow does.
I read the NIAMS description of inverse psoriasis: smooth patches of inflamed skin in a fold, and it names the groin among them. Rubbing and sweating can make it worse.
The International Psoriasis Council names the genitalia a high-impact site. On that scale, psoriasis there makes a person a candidate for systemic therapy whatever share of the body is covered. The National Psoriasis Foundation lists the genitals the same way.
That matters here in one practical way. This is a recognized site with recognized care, so it is fair to name at a visit and fair to name with a partner.
What research records about psoriasis and relationships
I read two studies worth knowing about, because each describes a pattern across a group rather than a verdict on you.
A 2021 study compared 201 married or divorced people. 100 had moderate-to-severe plaque psoriasis and 101 did not. More of the psoriasis group was divorced, and that group scored lower on every question of a marriage survey.
A 2015 study screened skin-clinic patients in 13 European countries. Clinical depression was about twice as common there as in a comparison group with no skin condition.
Neither study looked at dating, and neither says what will happen to you. What they do show is that this weight is measured. Dreading the conversation is not a private overreaction.
Lived experience - varies by person
When the reaction tells you about them
People I have heard from describe fearing a partner will be put off. You do not owe an apology, a medical lecture, or reassurance about someone else’s comfort.
Respectful curiosity is one thing. Flinching, jokes, pressure to explain, or refusing to touch you is another, and it is information about that person.
A poor response is not proof that you picked the wrong moment or the wrong words. You can answer, redirect, end the topic, or end the date.
Bringing this to a dermatologist
Intimacy is a legitimate part of a psoriasis appointment, not a detour from the skin.
I checked what NICE assesses: the skin, the nails, high-impact sites, the impact on daily life, and any joint concerns. The effect on your life is already in scope.
The National Psoriasis Foundation suggests bringing a symptom record, describing symptoms clearly, and noting changes in severity and in the areas affected. A record that names a fold or genital site raises the subject without a speech.
I read the AAD itch page, which records that treating the psoriasis itself is the most effective way to relieve itch. If itch is what interrupts intimacy or sleep, say it in those words.
Sources for the facts above: Evidence Evidence Evidence
Ask your care teamBring to your next visit
You can use these as written or change the words. Saving keeps a question on this device.
Psoriasis in a skin fold or the genital area is affecting intimacy for me. What are the treatment options for that site?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Itching is interrupting sex or sleep for me. What could we change about my psoriasis treatment to bring it down?
Saving keeps this on your device and needs JavaScript, which is off in this browser.If worry about a flare is keeping me from dating, who on my care team can help with that part?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- National Psoriasis FoundationPatient education · Patient education, tier 5Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The organization publishes patient education, but the editorial and funding independence of this page was not separately reviewed.
What this source supports
Supports that psoriasis is an immune-mediated disease. It causes inflammation in the body. Raised plaques and scale on the skin are the visible sign. Supports that an overactive immune system speeds up skin-cell growth. Skin cells normally take about a month to grow and shed. With psoriasis they do so in three or four days. Supports that psoriasis is a chronic, long-term disease with no cure.
What it does not support
Does not predict whether one person will clear, stay the same, or flare. Does not give a share of people who reach a period with little or no psoriasis, or how long such a period lasts. The page shows no visible byline or update date. The site copyright year, 2026, is used here.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- American Academy of DermatologyPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that stress can trigger a psoriasis flare. Supports that skin injury - a cut, scrape, sunburn, tattoo, piercing, bug bite, or shaving nick - can trigger a flare near or at that spot. Typically this appears about 10 to 14 days after the injury. Supports that an infection such as strep throat, an earache, or bronchitis can trigger a flare, reported 2 to 6 weeks later. Supports that starting a medication - including lithium, antimalarial drugs, strong corticosteroids, or some blood pressure drugs - can trigger a flare about 2 to 3 weeks after starting it. Supports that cold, dry weather (such as winter or fall) can worsen flares, and that sunburn or spending time in air conditioning can also worsen them. Supports that smoking, or spending time around secondhand smoke, is a reported trigger. Supports that drinking daily, or more than two drinks on several days a week, can make psoriasis treatment have little or no effect. Supports that triggers differ from person to person.
What it does not support
Does not cite a specific study for its trigger list or timing windows, and does not state how many patients experience each trigger. This page displays no revision date; the date recorded here matches the same AAD psoriasis disease microsite's treatment-and-diagnosis page, checked the same day. Does not establish that avoiding a listed trigger will prevent a flare for any one person.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Psoriasis FoundationPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that tracking symptoms and common triggers over time can help a person figure out their own specific triggers. Supports naming stress, alcohol, and diet as examples of common triggers to watch for. Supports naming discolored skin patches and itching as psoriasis symptoms, and joint swelling and fatigue as psoriatic arthritis symptoms, to watch for. Supports using a worksheet to record daily symptoms and their severity, and sharing that worksheet with a health care provider.
What it does not support
Does not give a percentage or timeline for how much tracking changes any one outcome. Does not name every possible trigger - stress, alcohol, and diet are examples, not a complete list. Does not measure whether tracking itself helps or burdens a given person.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Institute of Arthritis and Musculoskeletal and Skin DiseasesPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that poor sleep quality is a listed symptom of psoriasis. Also lists patches of thick, red, scaly skin that itch or burn, and dry, cracked skin that itches or bleeds. Supports that psoriasis carries risk for mental-health concerns including low self-esteem, anxiety, and depression. Supports that managing common triggers, such as stress and skin injuries, can help keep symptoms under control. Supports, by subtype, that guttate psoriasis outbreaks are often triggered by an upper respiratory infection such as strep throat. Also supports that pustular psoriasis symptoms can be triggered by medications, infections, stress, or certain chemicals. Also supports that erythrodermic psoriasis can be triggered by a bad sunburn or certain medications including corticosteroids. Also supports, by subtype, that inverse psoriasis appears as smooth patches of inflamed skin in skin folds. It names the armpits, the groin, and under the breasts as those folds. It records that rubbing and sweating can make inverse psoriasis worse.
What it does not support
Does not give a percentage of patients affected. Does not measure how much sleep is lost. Does not establish that treating the skin fixes the sleep problem for any one person. Its trigger information is organized by psoriasis subtype, not as one general list for plaque psoriasis specifically. It counts nothing for inverse psoriasis either. It gives no share of people affected in a fold or genital site, and it names no treatment for one.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- International Psoriasis CouncilGuideline · Clinical research, tier 2Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The International Psoriasis Council names its corporate members on its own site (psoriasiscouncil.org/about/corporate-members/, checked 2026-09-11). The top tier names AbbVie, Johnson & Johnson, Eli Lilly, Novartis and Takeda. LEO Pharma, UCB, Almirall, Sun Pharma, Amgen, Alumis, Arcutis and Oruka sit below them. Those firms make the drugs this severity rule opens the door to. A wider rule on who qualifies is a wider market for them. The page says nothing about how that money relates to IPC independence.
What this source supports
Supports that IPC dropped the mild, moderate and severe scale. In its place a person is a candidate for topical therapy, or a candidate for systemic therapy. Supports that any one of three criteria is enough to be a candidate for systemic therapy. The first is psoriasis on 10% or more of the body surface. The second is psoriasis on a high-impact site. IPC names those sites as the face, palms, soles, genitalia, scalp and nails. The third is failure of topical therapy. Supports that IPC defines that failure in writing. It is not reaching clear or almost-clear skin after two four-week courses in a row. IPC gives clear or almost-clear as 1% or less body surface, with a physician global assessment of 0 or 1. Supports the source paper. It is Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol 2020 Jan;82(1):117-122. Supports that IPC's own June 2025 teaching deck lists payers among the groups it set out to move. That deck also names refusal to pay as a result of the older scale.
What it does not support
Does not set any health plan's coverage rule. This is a professional-society consensus. It is not a regulation and not a plan document. Does not say which systemic treatment follows once a person meets a criterion. It sets no dose, no frequency and no schedule. Does not give the number of experts who voted, the response rate, or their conflict-of-interest disclosures. IPC's own June 2025 deck states the body-surface threshold two ways. Its criteria summary says 10% or more. The slide expanding that criterion says above 10%. Does not establish that a given reader meets a criterion. It predicts nothing about what a plan will decide.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Psoriasis FoundationPatient education · Patient education, tier 5Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The National Psoriasis Foundation names its corporate members on its own site (psoriasis.org/corporate-members/, checked 2026-09-09). They include AbbVie, Johnson & Johnson, Leo Pharma, Lilly, Novartis, UCB, Amgen, Sun Pharma, Arcutis, Bristol Myers Squibb, Takeda, and Alumis. Several of those firms make the drugs step therapy and copay-card rules affect. NPF also lobbies against both practices. This number and its framing come from a group with a stake in the fight, even though NPF says it does not back one drug over another.
What this source supports
Supports that NPF adopted a two-class definition. Mild psoriasis can be managed with topical therapies. Moderate-to-severe psoriasis makes a person a candidate for advanced therapies. Supports its statement that "Moderate-to-severe psoriasis is not determined solely by body surface area (BSA) involvement of 10%." Supports that psoriasis on a high-impact site counts too. NPF gives those sites as the face, scalp, hands, feet, nails or genitals. It says such patients "should also be considered as having 'moderate-to-severe' disease". Supports that the same holds for people who cannot get adequate control from topical therapies. Supports its statement that "People with psoriasis should never be denied advanced care because of outdated measures."
What it does not support
Does not set any health plan's coverage rule and does not bind a payer. Does not name prior authorization, appeals or denial steps. Gives no appeal deadline and no appeal process. Does not say how much topical treatment counts as inadequate control, or over what period. Does not establish that a given reader is a candidate for a named therapy. It predicts nothing about what a plan will decide.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Italian Journal of Dermatology and Venereology (Di Altobrando A, Vara G, Filippi F, Sacchelli L, Patrizi A, Bardazzi F)Observational study · Clinical research, tier 2Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The full text, including any funding or competing-interest disclosure, is not open access; only the indexed PubMed abstract could be verified.
What this source supports
Supports that a case-control study followed 201 married or divorced people: 100 with moderate-to-severe plaque psoriasis, 101 without. A significantly higher number of the psoriasis group was divorced. Supports that people with psoriasis scored lower than the comparison group on every question of the Quality Marriage Index, and on its total score. Supports that the survey question about how happy the marriage was weighed more heavily for people without psoriasis. Supports that the question about how strong the marriage was weighed more heavily for people with psoriasis.
What it does not support
Does not give a divorce rate or percentage for either group - only that the psoriasis group's number was significantly higher. One case-control study of 201 people, all from Italy. Studied moderate-to-severe plaque psoriasis only. Compares two groups on average; it does not predict any one relationship.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Journal of Investigative Dermatology (Dalgard FJ, Gieler U, Tomas-Aragones L)Observational study · Clinical research, tier 2Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: Funding and conflict notes were not checked beyond the published record. So the status here is set to not established.
What this source supports
Supports that skin-clinic patients in 13 European countries were screened. They were screened for low mood, for worry, and for thoughts of self-harm. A group with no skin problem was screened too. Supports that low mood was about twice as common in the patient group. Supports that worry was more common in the patient group. Supports that thoughts of self-harm were more common there too. Supports that psoriasis was one of the skin problems in the study.
What it does not support
Does not split psoriasis out from the other skin problems. Does not give a figure for psoriasis alone. It looked at people at one point in time. So it cannot show what came first. Does not judge or predict one person. It was run in Europe and does not describe US care today.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Institute for Health and Care ExcellenceGuideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports psoriasis assessment across skin, nails, high-impact sites, life impact and joint concerns; same-day specialist assessment for generalised pustular psoriasis or erythroderma; and a treatment map that includes topical, phototherapy and systemic options.
What it does not support
It is UK guidance and does not diagnose a reader, create a US treatment sequence, determine personal urgency from a description, or establish current US labeling or coverage.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Psoriasis FoundationPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports bringing a symptom tracker, kept on paper or on a phone, to share with a doctor at an appointment. Supports clearly describing symptoms and noting changes in severity and affected areas as part of preparing for a visit.
What it does not support
Does not mention photographing skin changes specifically. The page shows no visible byline or update date. The site copyright year, 2026, is used here.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- American Academy of DermatologyPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports treating the psoriasis itself as the most effective way to relieve itch. Supports moisturizing instead of scratching, especially after washing. Supports warm water, and showers of about 5 minutes or baths of about 15 minutes. Supports a cool, damp washcloth on itchy skin. Supports an anti-itch product with menthol or camphor as ingredients that tend to work well.
What it does not support
Does not quantify how much itch a given step relieves. Does not say an anti-itch product replaces psoriasis treatment.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.